A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?

Abstract

Abstract In a minority of relapsed myeloma, patient's disease may spread into extramedullary sites, associated with high degrees of heterogeneity. The breadth of myeloma therapeutic armamentarium allows clinicians to manage its heterogeneous presentation, including intracranial relapses, with fair success resulting in a significant prolongation of survival.

Keywords

• bortezomib
• extramedullary disease
• multiple myeloma
• refractoriness